3 Stocks That Could Benefit From the Ozempic Craze
Ozempic is a drug that has been soaring in popularity over the past year. Its ability to help people shed significant weight has turned it into a hot trend on social media, with people posting before-and-after pictures. And it appears demand for it is likely going to remain strong.
Three companies that can benefit from the excitement around this weight-loss treatments are Novo Nordisk (NYSE: NVO), Eli Lilly (NYSE: LLY), and WW International (NASDAQ: WW). Let's take a look at each one.
The biggest benefactor of Ozempic's popularity is likely to be the company that makes the treatment itself: Novo Nordisk. Demand for the treatment hasn't been slowing down. Analysts from JPMorgan Chase estimate that in the last week of January, U.S. doctors wrote over 313,000 prescriptions for it -- a 78% increase from the same period last year. Novo Nordisk has been increasing its capacity in order to keep up with orders.
Source Fool.com
